Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Different drug delivery agents, including synthetic polymers, virus-based vectors, lipid-based vectors, and extracellular vesicles (EVs), have been explored previously.
Stanford scientists have developed a working model that chemotherapy drugs induce peripheral neuropathy by activating a pathway that favors neuronal degeneration and impairs sensory neuron function.
Fiber photometry, a measurement technique that aggregates fluorescence signal using a fiber optic, is a highly pervasive approach in the field of systems neuroscience to study in vivo brain tissue dynamics during ecologically relevant behavior.
Inventors at Stanford have developed a novel strategy to perform concurrent fluorescence measurements of multiple biological parameters in freely moving and head-restrained animals.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Stanford researchers have identified an appropriate method and dosage for radiotherapy-based noninvasive lung volume reduction to treat severe emphysema.
Researchers at Stanford University have discovered a way to enhance the effectiveness of CAR-T cell therapeutics through inducing a more memory-like phenotype.
Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
Stanford researchers at the Zhao Lab have designed milli-spinner thrombectomy devices that mechanically debulk clots by safely shredding the clots for fast and complete clot removal.
Stanford researchers in the Zhao Lab have developed a mechanical thrombectomy device for Pulmonary Embolism (PE) that mechanically debulks and reduces volume of large clots without causing fragmentation.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.